Pacific Biosciences of California, Inc.

NasdaqGS:PACB Lagerbericht

Marktkapitalisierung: US$603.9m

Pacific Biosciences of California Management

Management Kriterienprüfungen 2/4

Pacific Biosciences of California CEO ist Christian O. Henry , ernannt in Sep 2020, hat eine Amtszeit von 4.17 Jahren. Die jährliche Gesamtvergütung beträgt $8.05M , bestehend aus 8.6% Gehalt und 91.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.14% der Aktien des Unternehmens, im Wert von $860.82K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4 Jahre bzw. 11.8 Jahre.

Wichtige Informationen

Christian O. Henry

Geschäftsführender

US$8.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts8.6%
Amtszeit als Geschäftsführer4.2yrs
Eigentum des Geschäftsführers0.1%
Durchschnittliche Amtszeit des Managements4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder11.8yrs

Jüngste Management Updates

Recent updates

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

Nov 12

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Nov 07
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Oct 16
Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Sep 20
Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

Aug 21

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

Jul 02
Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Jun 08
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Jun 03

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

Apr 25
These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Apr 16
It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01
With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18
What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13
Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28
The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06
Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29
Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Christian O. Henry im Vergleich zu den Einnahmen von Pacific Biosciences of California verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-US$394m

Jun 30 2024n/an/a

-US$400m

Mar 31 2024n/an/a

-US$297m

Dec 31 2023US$8mUS$695k

-US$307m

Sep 30 2023n/an/a

-US$309m

Jun 30 2023n/an/a

-US$319m

Mar 31 2023n/an/a

-US$321m

Dec 31 2022US$7mUS$667k

-US$314m

Sep 30 2022n/an/a

-US$299m

Jun 30 2022n/an/a

-US$206m

Mar 31 2022n/an/a

-US$175m

Dec 31 2021US$3mUS$650k

-US$181m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$59m

Dec 31 2020US$13mUS$195k

US$29m

Sep 30 2020n/an/a

-US$46m

Jun 30 2020n/an/a

-US$51m

Mar 31 2020n/an/a

-US$53m

Dec 31 2019US$100kn/a

-US$84m

Sep 30 2019n/an/a

-US$115m

Jun 30 2019n/an/a

-US$111m

Mar 31 2019n/an/a

-US$109m

Dec 31 2018US$88kn/a

-US$103m

Vergütung im Vergleich zum Markt: Christian O.Die Gesamtvergütung ($USD8.05M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD3.18M).

Entschädigung vs. Einkommen: Christian O.Die Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Christian O. Henry (56 yo)

4.2yrs

Amtszeit

US$8,046,575

Vergütung

Mr. Christian O. Henry, MBA, served as Independent Director at CM Life Sciences III Inc. since April 07, 2021 until December 2021. He has been President and Chief Executive Officer at Pacific Biosciences o...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Christian O. Henry
President4.2yrsUS$8.05m0.14%
$ 860.8k
Susan Kim
Chief Financial Officer4.2yrsUS$2.52m0.043%
$ 262.0k
Mark Van Oene
Chief Operating Officer3.8yrsUS$4.60m0.12%
$ 701.0k
Jeff Eidel
Chief Commercial Officer2.3yrsUS$2.53m0.050%
$ 299.7k
Stephen Turner
Co-Founder24.3yrsUS$466.76kkeine Daten
Michele Farmer
VP & Chief Accounting Officer3.5yrskeine Daten0.013%
$ 80.3k
Brett Atkins
General Counsel & Corporate Secretaryno datakeine Datenkeine Daten
Natalie Welch
Chief People Officerno datakeine Datenkeine Daten

4.0yrs

Durchschnittliche Betriebszugehörigkeit

49.5yo

Durchschnittliches Alter

Erfahrenes Management: PACBDas Führungsteam des Unternehmens gilt als erfahren (4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Christian O. Henry
President6.3yrsUS$8.05m0.14%
$ 860.8k
William Ericson
Independent Director20.8yrsUS$259.00k0.0069%
$ 41.7k
Lucy Shapiro
Independent Director12.2yrsUS$255.00k0%
$ 0
John Milligan
Independent Chairman11.3yrsUS$297.00k0.040%
$ 243.7k
Harry Gray
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Joseph Bonventre
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Randall Livingston
Independent Director15.8yrsUS$265.00k0%
$ 0
Harold Craighead
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Roger Kornberg
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Watt Webb
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Kenneth Johnson
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Jay Shendure
Chairman of Scientific Advisory Board2yrskeine Datenkeine Daten

11.8yrs

Durchschnittliche Betriebszugehörigkeit

70yo

Durchschnittliches Alter

Erfahrener Vorstand: PACBDie Vorstandsmitglieder sind sehr erfahren ( 11.8 ).